Basal Ganglia Diseases: Clinical Trials

5,523 trials for Basal Ganglia Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2912 completed, 859 unknown, 770 recruiting, 315 terminated. 2296 Not applicable, 832 Phase 2, 560 Phase 1, 378 Phase 3, 204 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable2296Completed 1093, Unknown 442, Recruiting 368, Not yet recruiting 120, Terminated 99, Active not recruiting 81, Enrolling by invitation 44, Withdrawn 44, Suspended 5
Phase 2832Completed 489, Unknown 83, Terminated 77, Recruiting 74, Active not recruiting 42, Withdrawn 31, Not yet recruiting 26, Enrolling by invitation 8, Suspended 2
Phase 1560Completed 349, Recruiting 58, Unknown 45, Terminated 37, Active not recruiting 24, Not yet recruiting 23, Withdrawn 20, Enrolling by invitation 3, Suspended 1
Phase 3378Completed 264, Terminated 46, Recruiting 24, Unknown 22, Active not recruiting 9, Withdrawn 8, Not yet recruiting 3, Enrolling by invitation 2
Phase 4204Completed 124, Unknown 32, Terminated 19, Recruiting 13, Enrolling by invitation 5, Not yet recruiting 5, Withdrawn 4, Active not recruiting 1, Suspended 1
Early Phase 183Completed 38, Recruiting 18, Unknown 9, Terminated 7, Not yet recruiting 5, Withdrawn 4, Active not recruiting 2

Follow Basal Ganglia Diseases: new trials by email Literature Review of Basal Ganglia Diseases trials Research Report on Basal Ganglia Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Terazosin And Metabolic Energetics in Parkinson's Disease
Terazosin 5 MG, Placebo - Parkinson's Disease (PD)
Phase 2SuspendedErgun Y. Uc1202028-07-012026-10-09
Double-Blind Clinical Trial of Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease
active subthalamic nucleus deep brain stimulation plus optimal drug therapy, inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy - Parkinson Disease
Not applicableNot yet recruitingMallory Hacker402028-01-012026-02-20
Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients.
Gemfibrozil, Placebo - Parkinson Disease
Phase 2WithdrawnForest Hills Lab2027-11-012026-08-19
Terazosin for Dementia With Lewy Bodies
Terazosin Hydrochloride, Placebo - Dementia With Lewy Bodies
Phase 1 / Phase 2Not yet recruitingQiang Zhang402027-10-012026-03-12
A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease
MT101-5 - Parkinson's Disease
Phase 2Not yet recruitingMthera Pharma Co., Ltd.1202027-09-012026-10-16
Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD)
rTMS - Parkinson Disease
Not applicableNot yet recruitingUniversity of Michigan202027-09-012026-10-20
Gastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics
Levodopa (L-dopa) - Parkinson's Disease
Phase 4Not yet recruitingBeth Israel Deaconess Medical Center402027-07-012026-08-28
Fecal MicrobiotaTransplant for the Treatment of Parkinson's Disease
Fecal Microbiota Transplant - Parkinson Disease
Phase 1Not yet recruitingProgenaBiome102027-07-012026-10-09
Engage-PD: a Physical Activity Coaching Program Via Telehealth for People With Parkinson's Disease. A Single-cohort Study in Spain.
Physical Activity Coaching - PARKINSON DISEASE (Disorder)
Not applicableNot yet recruitingHospital Clinic of Barcelona302027-06-012026-10-05
Sustained Release Oral Formulation For Treatment Of Parkinsons Disease
Formulation A, Formulation B, Formulation C - Healthy Volunteers
Phase 1 / Phase 2Not yet recruitingUniversity of Minnesota322027-04-012026-10-01
Expiratory Muscle Training in Parkinson's Disease With Forward Trunk Flexion
Expiratory muscle strength training - Parkinson's Disease
Not applicableNot yet recruitingGeneral University Hospital, Prague282027-02-012026-11-12
Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease
Huntington Disease
Not yet recruitingBioSensics752027-01-312026-10-13
A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD)
AB-1005 - Parkinson Disease
Phase 2Not yet recruitingBayer82027-01-252026-07-29
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB)
Not yet recruitingBioSensics602027-01-152026-10-13
Magnetic-Resonance Guided Focused Ultrasound Pallidothalamic Tractotomy for Parkinson's Disease
MR-guided Focused Ultrasound Pallidothalamic Tractotomy, MR-guided Focused Ultrasound VIM Thalamotomy, Combined MR-guided Focused Ultrasound PTT and VIM Treatment - Parkinson Disease (PD)
Not applicableNot yet recruitingResearch Center of Neurology, Russia1682027-01-152026-11-12
Strength and Dual-Task on Sarcopenia in People With Parkinson's Disease
Nutricional Education and General Exercise Guidelines, Progressive Resistance Training With Cognitive Dual-Task Training, Progressive Resistance Training With Cognitive Dual-Task and Inestability Training - PARKINSON DISEASE (Disorder), Parkinsonism or Parkinson's Disease Nos
Not applicableRecruitingUniversity of Valencia602027-01-112026-10-30
Exploring the Efficacy of the Effortful Swallow Maneuver for Improving Swallowing in People With PD
Effortful swallow - Dysphagia, Parkinson Disease (PD)
Not applicableNot yet recruitingUniversity of Alberta742027-01-012026-08-19
A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)
ONO-2808, Placebo - Multiple System Atrophy, Parkinson Variant
Phase 3Not yet recruitingOno Pharmaceutical Co., Ltd.4862027-01-012026-09-17
Probing Gut-Brain Communication in Parkinson's Disease
taVNS, Sham taVNS - Parkinson Disease (PD)
Not applicableNot yet recruitingSpaulding Rehabilitation Hospital452027-01-012026-10-08
Estimates of the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease
Talineuren, Placebo - Parkinson Disease
Phase 2Not yet recruitingInnoMedica Schweiz AG402027-01-012026-10-30

Showing 20 of 5523. Sign in to see all of them.

Narrower conditions

Parkinson Disease (4504)  ·  Huntington Disease (292)  ·  Lewy Body Disease (238)  ·  Tourette Syndrome (234)  ·  Alzheimer Disease (233)  ·  Parkinsonian Disorders (215)  ·  Multiple System Atrophy (204)  ·  Movement Disorders (184)  ·  Supranuclear Palsy, Progressive (171)  ·  Cognitive Dysfunction (167)  ·  Motor Activity (167)  ·  Dementia (153)  ·  Neurodegenerative Diseases (144)  ·  Dyskinesias (115)  ·  Depression (104)

Broader conditions

Central Nervous System Diseases (5471)  ·  Brain Diseases (5463)  ·  Nervous System Diseases (5439)  ·  Movement Disorders (5323)  ·  Neurodegenerative Diseases (5306)  ·  Synucleinopathies (4743)  ·  Parkinsonian Disorders (4507)  ·  Mental Disorders (1221)  ·  Pathological Conditions, Signs and Symptoms (1142)  ·  Signs and Symptoms (969)  ·  Neurologic Manifestations (827)  ·  Neurocognitive Disorders (785)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (660)  ·  Genetic Diseases, Inborn (648)

Interventions

Deep Brain Stimulation (93)  ·  Levodopa (90)  ·  Exercise (83)  ·  carbidopa, levodopa drug combination (74)  ·  Transcranial Direct Current Stimulation (57)  ·  Transcranial Magnetic Stimulation (56)  ·  Pramipexole (47)  ·  rasagiline (47)  ·  opicapone (43)  ·  rotigotine (43)  ·  Physical Therapy Modalities (37)  ·  Carbidopa (35)  ·  Control Groups (29)  ·  Apomorphine (27)  ·  Blood Specimen Collection (27)

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS) (77)  ·  Bial - Portela C S.A. (56)  ·  University of Florida (51)  ·  Boehringer Ingelheim (44)  ·  VA Office of Research and Development (42)  ·  Assistance Publique - Hôpitaux de Paris (41)  ·  Oregon Health and Science University (40)  ·  University Hospital, Toulouse (40)  ·  University of Minnesota (39)  ·  Washington University School of Medicine (37)  ·  Radboud University Medical Center (36)  ·  University of Colorado, Denver (34)  ·  AbbVie (33)  ·  Vanderbilt University Medical Center (33)  ·  Institut National de la Santé Et de la Recherche Médicale, France (32)

Countries

United States (2089)  ·  France (580)  ·  Italy (418)  ·  Germany (369)  ·  China (354)  ·  United Kingdom (350)  ·  Canada (349)  ·  Spain (286)  ·  Turkey (Türkiye) (176)  ·  Netherlands (146)  ·  Taiwan (141)  ·  Israel (134)  ·  Poland (116)  ·  Brazil (112)  ·  Austria (105)

Top investigators

Giuseppe Frazzitta, MD (18)  ·  Italo Biaggioni, MD (15)  ·  Danna Jennings, MD (12)

Results publications

PMID 36602886, PMID 38588457, PMID 40680102, PMID 31356217, PMID 36463457, PMID 38489195, PMID 25623333, PMID 29480210, PMID 30741694, PMID 31127735, PMID 32250312, PMID 10816186, PMID 19025984, PMID 19126811, PMID 27538531, PMID 28494751, PMID 31381524, PMID 34816053, PMID 36811812, PMID 38825840, PMID 41626017, PMID 11253156, PMID 12112073, PMID 12360555, PMID 12498954, PMID 1454205, PMID 15097290, PMID 16267188, PMID 16401616, PMID 16436781, PMID 17941858, PMID 19058133, PMID 20457959, PMID 20483969, PMID 20519680, PMID 20574039, PMID 20582993, PMID 20841416, PMID 20937936, PMID 20946640, PMID 21484867, PMID 21542016, PMID 22209649, PMID 22750016, PMID 22850494, PMID 22868933, PMID 23263599, PMID 23667214, PMID 23860343, PMID 24001701

NIH funding

2016 (20), 2023 (20), 2019 (18), 2018 (17), 2014 (15), 2025 (15), 2017 (14), 2009 (13), 2008 (12), 2015 (10), 2004 (7), 2005 (4), R01AG085029 (3), R01HL144568 (3), U01NS043128 (3)